# ScoreItem: ECG - Cornell Voltage - Homens (R aVL + S V3)

**ID:** `c77cedd3-2800-7c05-9ab4-7ab5fcf1cefb`
**FullName:** ECG - Cornell Voltage - Homens (R aVL + S V3) (Exames - Imagem)
**Unit:** mm
**Gender:** male

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 16 artigos
- Avg Similarity: 0.531

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `c77cedd3-2800-7c05-9ab4-7ab5fcf1cefb`.**

```json
{
  "score_item_id": "c77cedd3-2800-7c05-9ab4-7ab5fcf1cefb",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** ECG - Cornell Voltage - Homens (R aVL + S V3) (Exames - Imagem)
**Unidade:** mm
**G√™nero:** male

**30 chunks de 16 artigos (avg similarity: 0.531)**

### Chunk 1/30
**Article:** Predictive value of electrocardiographic left ventricular hypertrophy in the general population: A meta-analysis (2020)
**Journal:** Journal of Electrocardiology
**Section:** abstract | **Similarity:** 0.669

This meta-analysis examined electrocardiographic left ventricular hypertrophy (LVH) as a predictor of adverse cardiac outcomes in 58,400 participants across 10 studies. The Sokolow-Lyon voltage, Cornell voltage, and Cornell product criteria showed comparable ability in predicting major adverse cardiovascular events (MACE), with risk ratios ranging from 1.56 to 1.70. The pooled risk ratio of MACE was 1.62 (95% CI 1.40-1.89) for Sokolow-Lyon voltage criteria. The pooled risk ratio of all-cause mortality was 1.47 (95% CI 1.10-1.97), and cardiovascular mortality was 1.38 (95% CI 1.19-1.60) for Sokolow-Lyon criteria. Cornell voltage demonstrated stronger predictive value for cardiovascular and all-cause mortality outcomes.

---

### Chunk 2/30
**Article:** Left ventricular hypertrophy determined by Sokolow-Lyon criteria: a different predictor in women than in men? (2006)
**Journal:** Journal of Human Hypertension
**Section:** abstract | **Similarity:** 0.644

This prospective study examined 3,338 women and 3,330 men with hypertension over 11.2 years to assess whether ECG left ventricular hypertrophy (LVH) by Sokolow-Lyon voltage criteria predicted cardiovascular outcomes differently by gender. Increasing voltage independently predicted CVD mortality in both men and women. The risk of stroke, coronary heart disease (CHD) and cardiovascular disease (CVD) mortality increased significantly for each quantitative 0.1 mV increase in baseline ECG voltage, in women within the range of 1.6-3.9% and in men 1.4-3.0%. Women tended to have a high risk of stroke mortality owing to LVH, while men demonstrated stronger associations between voltage and coronary heart disease mortality.

---

### Chunk 3/30
**Article:** Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography (2015)
**Journal:** Journal of the American Society of Echocardiography
**Section:** abstract | **Similarity:** 0.551

Updated guidelines for echocardiographic assessment. Normal LVEF ‚â•54% in women by Simpson method. Sex-specific reference ranges are essential for accurate diagnosis of systolic dysfunction.

---

### Chunk 4/30
**Article:** Confounders in Identification and Analysis of Inflammatory Biomarkers in Cardiovascular Diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.551

atherosclerosis:Resultsfromaprospective,parallel-groupcohortstudy.Clin.Chim.Acta2015,447,16‚Äì22.[CrossRef]101.Hijazi,Z.;Lindahl,B.;Oldgren,J.;Andersson,U.;Lindb√§ck,J.;Granger,C.B.;Alexander,J.H.;Gersh,B.J.;Hanna,M.;Harjola,V.;etal.RepeatedMeasurementsofCardiacBiomarkersinAtrialFibrillationandValidationoftheABCStrokeScoreOverTime.J.Am.HeartAssoc.2017,6,e004851.[CrossRef]102.Abramson,J.L.;Lewis,C.;Murrah,N.V.;Anderson,G.T.;Vaccarino,V.RelationofC-ReactiveProteinandTumorNecrosisFactor-AlphatoAmbulatoryBloodPressureVariabilityinHealthyAdults.Am.J.Cardiol.2006,98,649‚Äì652.[CrossRef]103.Simundic,A.-M.;Kackov,S.;Miler,M.;Fraser,C.G.;Petersen,P.H.TermsandSymbolsUsedinStudiesonBiologicalVariation:TheNeedforHarmonization.Clin.Chem.2015,61,438‚Äì439.[CrossRef]
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

Biomolecules2021,11,1464
17of17
104.Khuseyinova,N.;Greven,S.;R√ºckerl,R.;Trischler,G.;Loewel,H.;Peters,A.;

---

### Chunk 5/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.550

(mm/mmHg)0.63¬±0.290.53¬±0.220.68¬±0.320.008Pericardialeffusion14(15.20%)7(23.30%)7(10.93%)0.11
VO2peak(ml*kg1*min1)(n=67)20.61¬±4.7018.89¬±4.9221.31¬±4.920.03NYHAclassII66(70.21%)21(70.00%)45(70.31%)0.98III23(24.46%)7(23.33%)16(25.00%)0.87
IV5(5.33%)2(6.67%)3(4.69%)0.65Aetiology(ischaemic)27(28.7%)17(56.7%)10(15.6%)0.01Yearofdisease5[2‚Äì10.75]4[1‚Äì9.75]7[2.75‚Äì12]0.1AF11(22.4%)4(13.33%)7(10.90%)0.73
Beta-blockers66(91.7%)24(72.00%)42(65.60%)0.15
ACE-I31(43.1%)12(40.00%)19(29.70%)0.22ARBs26(36.1%)9(30.00%)17(26.60%)0.72MRA26(36.1%)8(26.70%)18(28.12%)0.88
ICD26(36.6%)8(26.66%)18(28.10%)0.88
CRT10(14.1%)1(3.33%)9(14.10%)0.15IGF-1D50(53.2%)16(53.3%)34(53.1%)0.98DHEA-SD73(77.7%)29(97.7%)44(68.7%)0.01
TypeIIdiabetes26(27.7%)6(20%)20(31.2)0.37Abbreviations:TD,testosteronedeciency;NTproBNP,N-terminalproB-typenatriureticpeptide;BSA,bodysurfacearea;SBP,systolicbloodpressure;DBP,diastolicbloodpressure;eGFR,estimatedglomelurarltrationrate;LAVi,leftatrialvolumeindex;e,earlydiastolictransmit

---

### Chunk 6/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.549

N-terminalproB-typenatriureticpeptide;BSA,bodysurfacearea;SBP,systolicbloodpressure;DBP,diastolicbloodpressure;eGFR,estimatedglomelurarltrationrate;LAVi,leftatrialvolumeindex;e,earlydiastolictransmitralowvelocity;E‚Ä≤,earlydiastolicmitralannularvelocity;TAPSE,tricuspidannularplaneexcursion;PASP,pulmonaryarterialsystolicpressure;RVOT-AT,rightventricularoutowtractaccelerationtime;VO2peak,peakoxygenconsumption;NYHA,NewYorkHeartAssociation;AF,atrialbrillation;ACE-I,angiotensin-converting-enzymeinhibitors;ARBs,angiotensin-receptorblockers;MRA,mineralocorticoid-receptorantagonist;ICD,implantablecardioverter-debrillator;CRT,cardiacresynchronizationtherapy;IGF-1D,IGF-1deciency;DHEA-SD,DHEA-Sdeciency.

---

### Chunk 7/30
**Article:** Hipertens√£o Arterial Sist√™mica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.545

tens√£o Est√°gio 1:** 140-159 / 90-99 mmHg.
        *   **Hipertens√£o Est√°gio 2:** 160-179 / 100-109 mmHg.
        *   **Hipertens√£o Est√°gio 3:** ‚â• 180/110 mmHg.
### 3. Tratamento N√£o Farmacol√≥gico: A Base da Terapia
*   **Princ√≠pio Fundamental:** A mudan√ßa no estilo de vida √© recomendada para TODOS os est√°gios de press√£o arterial, desde o diagn√≥stico.
*   **Principais Interven√ß√µes:**
    *   **Controle de Peso:** Cada 1 kg perdido reduz a PA em 1 mmHg.
    *   **Dieta Saud√°vel:** Recomenda-se uma dieta anti-inflamat√≥ria e low-carb, que aborda a resist√™ncia insul√≠nica. Pode reduzir a PA em 3-5 mmHg.
    *   **Atividade F√≠sica:** 150 minutos de atividade aer√≥bica/semana podem reduzir a PA em 5-7 mmHg.
    *   **Redu√ß√£o do √Ålcool:** Contribui para a diminui√ß√£o da press√£o.
    *   O potencial combinado dessas mudan√ßas pode reduzir a press√£o em 30 a 40 mmHg.
*   **A Pol√™mica do S√≥dio vs.

---

### Chunk 8/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.537

dade, inatividade f√≠sica, press√£o arterial e dislipidemia.
- A inflama√ß√£o √© indicada por marcadores como a Prote√≠na C-Reativa (PCR), onde um valor de 5 j√° √© considerado elevado, e a Interleucina 6 (exemplo de paciente com 8.45).
- A resposta anti-inflamat√≥ria √© medida pela Interleucina 10, com um valor de corte de 3,5 (abaixo disso √© um risco) e um exemplo de paciente com 6.44.
- A sa√∫de do endot√©lio √© avaliada pelo √≥xido n√≠trico, que deve estar em 8.8; um paciente com 4.8 j√° apresenta disfun√ß√£o sist√™mica.
- A LDL oxidada √© um marcador cr√≠tico, com um limite saud√°vel de 133, enquanto pacientes de alto risco podem apresentar valores extremos, como 1000.
**Achados Adicionais**
- Existem cinco par√¢metros cl√°ssicos para definir a s√≠ndrome metab√≥lica.
- O alvo de LDL para pacientes de alto risco, segundo as diretrizes atuais, √© de 50.

---

### Chunk 9/30
**Article:** Aula Afonso Salgado - Sistema nervoso aut√¥nomo (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.535

ia√ß√£o descrito inclui:

- Exame realizado preferencialmente pela manh√£, em jejum, evitando a ingest√£o de medicamentos naquele momento (pois alteram a leitura).  
- Repeti√ß√£o do exame em **3 a 5 ocasi√µes** em condi√ß√µes semelhantes, para obter dados de ‚Äúpadr√£o ouro‚Äù (maior confiabilidade).  

A partir do ECG, softwares especializados analisam a VFC tanto no **dom√≠nio do tempo** quanto no **dom√≠nio da frequ√™ncia**:

- No dom√≠nio do tempo, o par√¢metro mais citado √© o **SDNN** (desvio padr√£o dos intervalos NN), que √© uma raiz quadrada aplicada √† distribui√ß√£o dos intervalos.  
- SDNN mais alto indica maior variabilidade; SDNN baixo indica rigidez do ritmo, associada a pior progn√≥stico.

No dom√≠nio da frequ√™ncia, embora Afonso n√£o detalhe numericamente, ele indica o uso de t√©cnicas matem√°ticas como:

- **R√°pida transformada de Fourier (FFT)**,  
- **wavelet transform**,  
- **ritmogramas** (conceito de origem russa).

---

### Chunk 10/30
**Article:** Hipertens√£o Arterial Sist√™mica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.530

*Classes Preferenciais:** IECA (Inibidores da Enzima Conversora de Angiotensina), BRA (Bloqueadores do Receptor de Angiotensina), diur√©ticos tiaz√≠dicos e bloqueadores do canal de c√°lcio. A combina√ß√£o entre eles √© a melhor estrat√©gia. A associa√ß√£o de IECA com BRA √© proibida.
*   **Hierarquia Terap√™utica:**
    1.  Mudan√ßa de estilo de vida.
    2.  IECA/BRA, bloqueador de canal de c√°lcio ou diur√©tico tiaz√≠dico.
    3.  Espironolactona (4¬™ op√ß√£o).
    4.  Betabloqueador (5¬™ op√ß√£o).
*   **Betabloqueadores:** N√£o s√£o mais primeira linha. T√™m menor prote√ß√£o cardiovascular, aumentam o risco de diabetes e causam efeitos adversos (disfun√ß√£o sexual, ganho de peso). S√£o considerados rem√©dios de exce√ß√£o.
*   **Metas Terap√™uticas:**
    *   **Alto risco:** Manter PA entre 120/70 e 130/80 mmHg.
    *   **Baixo/moderado risco e idosos h√≠gidos:** Manter PA at√© 140/90 mmHg.

---

### Chunk 11/30
**Article:** Hipertens√£o Arterial Sist√™mica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.530

s no estilo de vida oferecem um potencial de redu√ß√£o da press√£o arterial de at√© 40 mmHg, enquanto o tratamento farmacol√≥gico reduz significativamente o risco de AVC (34%) e infarto (21%).**
- A perda de peso pode reduzir a press√£o em 1 mmHg por quilo perdido, com um potencial de at√© 20 mmHg para uma perda de 20 kg.
- Atividade f√≠sica aer√≥bica (150 minutos/semana) pode reduzir a press√£o em 5 a 7 mmHg.
- Dietas e restri√ß√£o de s√≥dio podem levar a uma redu√ß√£o de 2 a 6 mmHg.
- As metas de tratamento variam: abaixo de 14/9 para baixo risco, 120-130 / 70-80 mmHg para alto risco e at√© 160/90 para idosos fr√°geis.

---

### Chunk 12/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.530

diseasedurationandlowdensitylipoproteincholesterollevels.JAmCollCardiol
1996:28:573‚Äì579.50Pedersen&Saltin
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

CoakleyEH,RimmEB,ColditzG,KawachiI,WillettW.Predictorsofweightchangeinmen:resultsfrom
theHealthProfessionalsFollow-upStudy.IntJObesRelatMetabDisord1998:22:89‚Äì96.CoatsAJ,AdamopoulosS,MeyerTE,ConwayJ,SleightP.Effectsofphysicaltraininginchronicheartfailure.Lancet1990:335:63‚Äì66.CoatsAJ,AdamopoulosS,RadaelliA,McCanceA,MeyerTE,BernardiL,SoldaPL,DaveyP,OrmerodO,ForfarC.Controlledtrialofphysical
traininginchronicheartfailure.

---

### Chunk 13/30
**Article:** Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome (2019)
**Journal:** Journal of the American College of Cardiology
**Section:** results | **Similarity:** 0.524

gnostics,andSingulex.All
otherauthorshavereportedthattheyhavenorelationshipsrelevanttothecontentsofthispapertodisclose.ManuscriptreceivedJuly11,2019;revisedmanuscriptreceivedJuly25,2019,acceptedJuly28,2019.JACCVOL.74,NO.16,2019Leeetal.OCTOBER22,2019:2032‚Äì43Sex-SpecicThresholdsofhs-cTnI2033

internationalguidelinesinuseduringenrollment(9,10).Throughoutthedurationofthetrial,allsitesmeasuredcardiactroponinusingboththecTnIand
hs-cTnIassayssimultaneously.Duringthevalidation
phase,onlytheresultsofthecTnIassaywerere-portedtotheattendingclinician,whileduringtheimplementationphase,onlytheresultsofthehs-cTnIassaywerereported.ThecTnIassay(ARCHITECTSTATtroponinIassay;AbbottLaboratories,AbbottPark,Illinois)with
asinglediagnosticthresholdforwomenandmen
wasusedtoguideclinicaldecisionsduringthevali-
dationphase.Theinterassaycoefcientofvariationwas<10%at40ng/lat7sitesand50ng/lat3sites,andtheseconcentrationswereusedasthediagnostic
thresholdsduringthevalidationphase(11).Duringtheimplementationphase,a

---

### Chunk 14/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.521

from125to250pg/ml,whileforthoseover75years,itextendsfrom125to500pg/ml.Itiscrucialtoconductathoroughevaluationofpatientswithinthegreyzone,consideringfactorssuchasobesity,race-basedvariations,andongoingtreatment(asmanypatientswithahistory
ofhypertensionmayalreadybeondiuretics,renin‚Äìangiotensin
systeminhibitors,ormineralocorticoidreceptorantagonists).Intheoutpatientsetting,theextentofelevationinNPconcen-trationsatthetimeofheartfailurediagnosisiscloselylinkedtothe
riskofsubsequenthospitalizationandmortality.16Asaresult,therehasbeenasuggestiontoutilizeNT-proBNPconcentrationsatthe
timeofacommunity-basedheartfailurediagnosisasatriagingtooltoprioritizeaccesstoexpediteddiagnosticechocardiogra-phyandtosetupafollow-upplanforindividualswiththehighest
short-termriskofadverseevents.Theauthorsofthisconsensus
documentalignwiththeNICEguidelinesonchronicheartfailure,
whichrecommendacut-offvalueofNT-proBNP>2000pg/ml.40InananalysisofprimarycaredatafromEngland,anNT-proBNPvalue
of>2000pg/mlwasassociatedwi

---

### Chunk 15/30
**Article:** Hipertens√£o Arterial Sist√™mica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.520

causa secund√°ria identific√°vel.
**O diagn√≥stico e a classifica√ß√£o da hipertens√£o seguem limiares espec√≠ficos que variam conforme o m√©todo de medi√ß√£o, com est√°gios progressivos que orientam a terapia.**
- A press√£o arterial √© classificada como √≥tima (abaixo de 120/80 mmHg), normal (at√© 129/84 mmHg) e pr√©-hipertens√£o (130-139 / 85-89 mmHg).
- O diagn√≥stico de hipertens√£o √© estabelecido a partir de 14 por 9 mmHg em medi√ß√µes de consult√≥rio, aplic√°vel a indiv√≠duos com mais de 18 anos.
- Os est√°gios da hipertens√£o s√£o definidos como: Est√°gio 1 (a partir de 14/9), Est√°gio 2 (a partir de 16/10) e Est√°gio 3 (acima de 18/11).
- Para exames fora do consult√≥rio, os limiares s√£o mais baixos: 13 por 8 mmHg para o MAPA (24 horas) e 13 por 8,5 mmHg para o MRPA.

---

### Chunk 16/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.519

sensus
documentalignwiththeNICEguidelinesonchronicheartfailure,
whichrecommendacut-offvalueofNT-proBNP>2000pg/ml.40InananalysisofprimarycaredatafromEngland,anNT-proBNPvalue
of>2000pg/mlwasassociatedwithamorethantwo-foldhigherriskofheartfailurehospitalizationand50%higherriskofmortalityascomparedwithanNT-proBNPof400‚Äì2000pg/ml.47Wesug-gestthat,irrespectiveofageandsex,patientswithanNT-proBNP
>2000pg/mlshouldbeprioritizedforechocardiographyandclini-calevaluationwithin2weeksofdiagnosis(Figure2).NT-proBNPinasymptomaticpatientswithriskfactors:heart
stressVariousriskfactors,suchashypertension,atheroscleroticcardio-vasculardisease,diabetes,obesity,andothers,contributetoanincreasedsusceptibilitytothedevelopmentofheartfailure.Intheabsenceofsymptomsofheartfailure,patientswithriskfactorsmay
exhibiteitherhearthealthorheartstress.Hearthealthrefersto
individualswhohaveastructurallynormalheartandnormalplasma
concentrationsofNPsandtroponins.¬©2023EuropeanSocietyofCardiology.

---

### Chunk 17/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.518

m DCV), condi√ß√µes gestacionais (pr√©-termo, hipertensivas, diabetes gestacional), autoimunidade, tratamento de c√¢ncer de mama e defici√™ncias hormonais (climat√©rio/menopausa), frequentemente subvalorizadas nos protocolos. O palestrante defende abordagem multidisciplinar e estruturada de estilo de vida, especialmente em hipertens√£o lim√≠trofe, apoiada por nutricionistas e educa√ß√£o para ades√£o.
O uso de estatinas √© discutido criticamente: reconhece-se benef√≠cio anti-inflamat√≥rio local no p√≥s-angioplastia (les√£o de parede e fragilidade do stent), por√©m questiona-se o uso indiscriminado, sobretudo em preven√ß√£o prim√°ria, citando meta-an√°lise que desafia a hip√≥tese lip√≠dica e alertando para vieses na interpreta√ß√£o de risco relativo vs. absoluto. Em UTI, menciona-se aumento de del√≠rio e a necessidade de evitar ‚Äúreceita de bolo‚Äù (anticoagula√ß√£o, IBP, estatina autom√°tica).

---

### Chunk 18/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.516

¬±SDMean¬±SDMean¬±SDAge(years)66.18¬±10.2668.93¬±9.74564.89¬±10.3250.12NTproBNP(pg/ml)2597.05¬±4093.042794.47¬±3380.142504.52¬±4409.550.72
BSA(m2)1.70¬±0.161.68¬±0.11.71¬±0.190.34SBP(mmHg)123.29¬±17.82121.32¬±16.86124.24¬±18.370.53DBP(mmHg)75.46¬±12.3975.05¬±9.5175.65¬±13.650.85
eGFR(ml/min)68.61¬±34.2854.27¬±23.0275.55¬±36.760.001
Haemoglobin(g/dl)12.85¬±1.5312.50¬±1.2113.01¬±1.650.13Albumin(%)56.8¬±5.256.6¬±7.756.9¬±3.70.9Testosterone(ng/dl)48.80¬±61.8613.60¬±6.6362.55¬±68.16<0.001Ejectionfraction(%)33.81¬±6.4633.20¬±7.6634.10¬±5.850.53
LAVi(ml/m2)49.46¬±25.5755.51¬±30.2446.63¬±22.770.17e/E‚Ä≤14.68¬±9.9613.04¬±4.9512.53¬±6.400.16TAPSE(mm)18.82¬±4.5117.78¬±4.2619.31¬±4.560.12
PASP(mmHg)34.38¬±13.2537.69¬±13.7232.84¬±12.840.98
RVOT-AT(ms)103.27¬±36.47112.11¬±34.7497.15¬±37.730.35TAPSE/PASP(mm/mmHg)0.63¬±0.290.53¬±0.220.68¬±0.320.008Pericardialeffusion14(15.20%)7(23.30%)7(10.93%)0.11
VO2peak(ml*kg1*min1)(n=67)20.61¬±4.7018.89¬±4.9221.31¬±4.920.03NYHAclassII66(70.21%)21(70.00%)45(70.31

---

### Chunk 19/30
**Article:** Dislipdemia (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.515

quais ~250 mil ocorrem antes dos 60 anos.
- Brasil: 410 mil mortes/ano por DCV; 14 milh√µes com alguma DCV; 36% dos √≥bitos ‚â•55 anos decorrem de doen√ßa cardio-circulat√≥ria.
- Fisiopatologia: fluxo arterial torna-se turbilhonado ~50% de estenose, aumentando estresse de parede e risco de ruptura de placa.
**Achados Adicionais**
- LDL alvo em baixo risco: diretriz sugere <130 mg/dL (por vezes <100), mas o n√∫mero isolado n√£o determina benef√≠cio sem DCV pr√©via e sem avalia√ß√£o de part√≠culas/c√°lcio.
- LDL basal em estudo: 190 mg/dL; colesterol total 275 e HDL 31, ilustrando perfis iniciais elevados; em pacientes com c√°lcio zero, LDL >240 n√£o alterou mortalidade/infarto com estatina.

---

### Chunk 20/30
**Article:** Cardiologia VI (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.513

es com insufici√™ncia card√≠aca congestiva, conforme um estudo de 2010 com acompanhamento de 6 meses.
**A obesidade e a resist√™ncia insul√≠nica emergem como fatores de risco independentes e severos, aumentando a chance de hipertens√£o em 3,5 vezes e reduzindo a expectativa de vida em at√© 20 anos em casos de obesidade m√≥rbida.**
- Pacientes obesos com s√≠ndrome metab√≥lica apresentam um risco de mortalidade 18% maior e uma redu√ß√£o na expectativa de vida de 5 a 20 anos.
- Um estudo de 2017 mostrou que pacientes obesos com s√≠ndrome metab√≥lica t√™m 3,5 vezes mais chances de se tornarem hipertensos.
- A resist√™ncia insul√≠nica foi identificada como um fator de risco para doen√ßa cardiovascular j√° em 1996 e foi prevalente em 26% das pacientes n√£o diab√©ticas com c√¢ncer de mama em um estudo de 2012-2014 com 760 mulheres.

---

### Chunk 21/30
**Article:** Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome (2019)
**Journal:** Journal of the American College of Cardiology
**Section:** results | **Similarity:** 0.512

dline).Patientsaregroupedaccordingtowhethermyocardialinjurywaspresent(red)orabsent(gray).Pairedlog-ranktestresultsarep¬º0.40forwomenwithmyocardialinjuryandp¬º0.08forwomenwithoutmyocardialinjury.JACCVOL.74,NO.16,2019Leeetal.OCTOBER22,2019:2032‚Äì43Sex-SpecicThresholdsofhs-cTnI2039

infarctioninwomenandmen(15).Theimpactofsex-specicthresholdsonthediagnosisofmyocardialinfarctionhasbeenevaluatedinanumberofobser-vationalstudieswithdivergentndings(7,16‚Äì20).Mostofthesestudiesenrolledselectedpatientswith
acutecoronarysyndrome,ofwhomthemajoritywere
men.Furthermore,sex-specicthresholdswerenotusedtoguideclinicalcareorsubsequentinvestiga-
tionforcoronaryarterydisease.Here,weimple-
mentedsex-specicthresholdsintoroutineclinicalcareinarandomizedcontrolledtrialandevaluatedtheirimpactinconsecutivepatientspresentingwith
suspectedacutecoronarysyndrome.Wefoundthat
useofsex-specicthresholdsidentiedproportion-atelymorewomen,suchthattheoverallpercentages
ofwomenandmenidentiedashavingmyocardialinjury

---

### Chunk 22/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.512

easeof20mmHgin
systolicbloodpressureor10mmHgindiastolic
bloodpressurehalvestheriskofcardiovascularmor-
tality.Thus,forexample,apersonwithsystolicbloodpressureof120mmHghashalftheriskofcar-diovascularmortalityasapersonwithsystolicbloodpressureof140mmHg(Lewingtonetal.,2002).HypertensionisdeÔ¨Ånedassystolicbloodpressure
>140anddiastolicbloodpressure>90mmHg.AccordingtothisdeÔ¨Ånition,about20%ofthepopu-
lationhavehighbloodpressureorrequireblood
pressure-loweringmedication(Burtetal.,1995).However,theborderlinesbetweenoptimalandnor-malbloodpressureandbetweenmild,moderate,and
severehypertensionarearbitrary(Burtetal.,1995).

---

### Chunk 23/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.510

il√¢ncia aumentada nas mulheres.**
- Pr√©-menopausa: incid√™ncia de eventos cardiovasculares em mulheres √© muito menor (raz√µes 1:20 a 1:30 versus homens).
- P√≥s-menopausa: aproxima√ß√£o para quase 1:1, refletindo a perda do efeito protetor do estrog√™nio e a mudan√ßa no perfil de risco.
**Additional Key Findings**
- Limiares de exposi√ß√£o/oxida√ß√£o do LDL: acima de 0,8 h√° maior exposi√ß√£o do LDL √† oxida√ß√£o; alvo desej√°vel ‚â§0,7‚Äì0,8.
- Evid√™ncia hist√≥rica (Interarte, 2004) e revis√µes recentes (2023) sustentam a evolu√ß√£o do conhecimento sobre D, resist√™ncia √† insulina e risco cardiovascular.
- Lp(a) tem ~90% de variabilidade gen√©tica, indicando forte determina√ß√£o heredit√°ria e necessidade de estrat√©gias espec√≠ficas.
- Semaglutida em IC diast√≥lica e obesidade: estudo com n=529 mostrou redu√ß√£o de peso de 10% e apenas 1 evento de morte por IC no grupo tratado, sugerindo benef√≠cio cl√≠nico.

---

### Chunk 24/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** introduction | **Similarity:** 0.507

ontraindicationsThefollowingcontraindicationsareinagreementwithaEuropeanWorkingGroup(Gianuzzi&
Tavazzi2001).ÔøΩAcuteCHU(AMIorunstableangina),untilthe
conditionhasbeenstableforatleast5daysÔøΩDyspneaatrestÔøΩPericarditis,myocarditis,endocarditisÔøΩSymptomaticaorticstenosisÔøΩSeverehypertension.Thereisnoestablished,docu-
mentedborderlinebloodpressurevaluedeemedto
bethecut-offpointforincreasedrisk.Generallyit
isrecommendedthatdemandingphysicalexercise
beavoidedinthecaseofsystolicBP>180ordias-
tolicBP>105mmHgÔøΩFeverÔøΩSeriousnon-cardiacdiseaseHeartfailureBackgroundHeartfailureisaconditionwheretheheartisunabletopumpsufÔ¨ÅcientlytomaintainbloodÔ¨Çowtomeetthemetabolicneedsoftheperipheraltissue(Braun-
wald&Libby,2008).Heartfailureisaclinicalsyn-
dromewithsymptomssuchasÔ¨Çuidretention,
breathlessness,orexcessivetirednesswhenrestingor
exercising,andwithobjectivesymptomsofreduced
systolicfunctionoftheleftventricleatrest.Asymptomaticleftventriculardysfunctionisoftentheprecursorofthissyndrome.Sympt

---

### Chunk 25/30
**Article:** Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.507

rtJ.2014;35(37):2541-2619.doi:10.1093/eurheartj/ehu27876.ManciaG,FagardR,NarkiewiczK,etal.2013ESH/ESCGuidelinesfortheManagementofArterial
Hypertension:theTaskForcefortheManagement
ofArterialHypertensionoftheEuropeanSocietyof
Hypertension(ESH)andoftheEuropeanSocietyof
Cardiology(ESC).EurHeartJ.2013;34(28):2159-2219.doi:10.1093/eurheartj/eht15177.StegPG,JamesSK,AtarD,etal;TaskForceontheManagementofST-SegmentElevationAcute
MyocardialInfarctionoftheEuropeanSocietyof
Cardiology(ESC).ESCGuidelinesforthe
ManagementofAcuteMyocardialInfarctionin
PatientsPresentingWithST-SegmentElevation.EurHeartJ.2012;33(20):2569-2619.doi:10.1093/eurheartj/ehs21578.PerkJ,DeBackerG,GohlkeH,etal;EuropeanAssociationforCardiovascularPrevention&
Rehabilitation(EACPR);ESCCommitteeforPractice
Guidelines(CPG).EuropeanGuidelineson
CardiovascularDiseasePreventioninClinical
Practice(version2012).EurHeartJ.2012;33(13):1635-1701.doi:10.1093/eurheartj/ehs09279.McMurrayJJ,AdamopoulosS,AnkerSD,etal;ESCCommitteeforPracticeGuide

---

### Chunk 26/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.507

fortheman-
agementofheartfailure:Areportof
theAmericanCollegeofCardiologyFoundation/AmericanHeartAssociationtaskforceonpracticeguidelines.JAmCollCardiol.2013;62:e147‚Äìe239.3.BealeAL,MeyerP,MarwickTH,LamCSP,KayeDM.Sexdifferencesincardio-vascularpathophysiology:Whywomen
areoverrepresentedinheartfailurewith
preservedejectionfraction.Circulation.2018;138:198‚Äì205.4.ShahKS,XuH,MatsouakaRA,BhattDL,HeidenreichPA,HernandezAF,Devore
AD,YancyCW,FonarowGC.Heartfail-urewithpreserved,borderline,andre-ducedejectionfraction:5-yearout-
comes.JAmCollCardiol.2017;70:2476‚Äì2486.5.HsichEM,Grau-SepulvedaMV,HernandezAF,PetersonED,Schwamm
LH,BhattDL,FonarowGC.Sex
differencesinin-hospitalmortalityinacutedecompensatedheartfailurewithreducedandpreservedejection
fraction.AmHeartJ.2012;163:430‚Äì437.e3.6.CittadiniA,SalzanoA,IacovielloM,TriggianiV,RengoG,CacciatoreF,
MaielloC,LimongelliG,MasaroneD,
PerticoneF,CimellaroA,PerroneFilardiP,PaolilloS,ManciniA,VolterraniM,VrizO,CastelloR,PassantinoA,Campo
M,ModestiPA

---

### Chunk 27/30
**Article:** Hipertens√£o Arterial Sist√™mica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.505

est√°gios de hipertens√£o e press√£o arterial, independente do valor, tem que fazer ao diagn√≥stico mudan√ßa do estilo de vida. ‚Äî Speaker 1
### Terap√™utica e escolhas de medica√ß√£o
> IECA, BRA, diur√©tico tiaz√≠dico, e bloqueador do canal de c√°lcio, s√£o as quatro drogas preferenciais no tratamento da hipertens√£o e voc√™ fazer uma combina√ß√£o entre elas √© o melhor esquema. ‚Äî Speaker 1

---

### Chunk 28/30
**Article:** Hipertens√£o Arterial Sist√™mica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.504

nal (sistema renina-angiotensina-aldosterona - SRAA), renal, microbiota e endot√©lio.
    *   **Mecanismos de Controle:** R√°pidos (neurais), m√©dio prazo (hormonais, alvo principal dos f√°rmacos) e longo prazo (controle de volemia pelo rim).
*   **Diagn√≥stico e Classifica√ß√£o:**
    *   A medi√ß√£o em consult√≥rio √© criticada; recomenda-se MAPA (Monitoriza√ß√£o Ambulatorial) ou MRPA (Monitoriza√ß√£o Residencial) para um diagn√≥stico preciso.
    *   **Valores de Refer√™ncia para Diagn√≥stico:** ‚â• 140/90 mmHg (consult√≥rio), ‚â• 130/80 mmHg (MAPA 24h), ‚â• 135/85 mmHg (MRPA).
    *   **Classifica√ß√£o (a partir de 18 anos):**
        *   **√ìtima:** < 120/80 mmHg.
        *   **Normal:** 120-129 / 80-84 mmHg.
        *   **Pr√©-hipertens√£o:** 130-139 / 85-89 mmHg.
        *   **Hipertens√£o Est√°gio 1:** 140-159 / 90-99 mmHg.
        *   **Hipertens√£o Est√°gio 2:** 160-179 / 100-109 mmHg.
        *   **Hipertens√£o Est√°gio 3:** ‚â• 180/110 mmHg.
### 3.

---

### Chunk 29/30
**Article:** Dislipdemia (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.504

enta online que usa par√¢metros cl√≠nicos e o escore de c√°lcio para estimar o risco cardiovascular em 10 anos. Possui limita√ß√µes por n√£o incluir marcadores da medicina integrativa.
*   **Uso Criterioso de Estatinas:**
    - **Preven√ß√£o Prim√°ria (baixo risco):** O uso √© controverso e muitas vezes desnecess√°rio, pois o NNT √© muito alto e os riscos de efeitos adversos podem superar os benef√≠cios.
    - **Preven√ß√£o Secund√°ria (p√≥s-evento):** O uso √© justificado pelo baixo NNT e pelos **efeitos pleotr√≥picos** da estatina, que incluem:
        - Redu√ß√£o da inflama√ß√£o e melhora da fun√ß√£o endotelial.
        - Diminui√ß√£o da oxida√ß√£o dentro da placa.
        - Estabiliza√ß√£o da placa, tornando-a menos propensa √† ruptura.
*   **Exames Cl√≠nicos Avan√ßados:**
    - **Subfracionamento das part√≠culas de LDL e HDL:** Avalia o tamanho e a quantidade das part√≠culas.
    - **Anti-LDL Oxidado:** Mede a taxa de oxida√ß√£o do colesterol.

---

### Chunk 30/30
**Article:** Prognostic Significance of Left Atrial Volume Index in Acute Coronary Syndrome (2024)
**Journal:** Journal of the Practice of Cardiovascular Sciences
**Section:** abstract | **Similarity:** 0.502

Study demonstrating that LAVI acts as a powerful prognostic marker of adverse events and mortality in patients with acute coronary syndrome. Patients with increased LAVI have significantly worse long-term prognosis. Severe LA enlargement (LAVI >48 mL/m¬≤) was an independent predictor of all-cause mortality (HR: 11.153; 95% CI: 1.924-64.642, p=0.007).

---

